Apellis Pharmaceuticals, Inc. (APLS)
| Market Cap | 2.99B |
| Revenue (ttm) | 1.02B |
| Net Income (ttm) | 44.99M |
| Shares Out | 126.53M |
| EPS (ttm) | 0.36 |
| PE Ratio | 65.98 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,341,146 |
| Open | 22.13 |
| Previous Close | 22.19 |
| Day's Range | 22.02 - 24.08 |
| 52-Week Range | 16.10 - 35.72 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 33.11 (+40.12%) |
| Earnings Date | Oct 30, 2025 |
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce... [Read more]
Financial Performance
In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for APLS stock is "Buy." The 12-month stock price target is $33.11, which is an increase of 40.12% from the latest price.
News
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase...
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conf...
Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript
Apellis Pharmaceuticals, Inc. ( APLS) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President ...
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continu...
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, Nove...
Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. ( APLS) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - E...
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robus...
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced th...
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
Apellis Pharmaceuticals maintains a strong "Buy" rating for me, driven by robust SYFOVRE sales and recent EMPAVELI FDA approvals for rare kidney diseases. APLS is expanding SYFOVRE's potential with a ...
Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Baird Global Healthcare Conference September 9, 2025 10:15 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sull...
Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Cantor Global Healthcare Conference 2025 September 4, 2025 8:35 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy...
Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Ex...
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, Pre...
Apellis Pharmaceuticals: The Picture Becomes Clearer
Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals fo...
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2025 financial results and business highlights.
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.'s APLS Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex memb...
FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) a...
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2...
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina...
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
STOCKHOLM , July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obliga...
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $30...